HTLV-1 infection and microRNAs: unraveling the complex crosstalk.

IF 3.1 2区医学 Q3 IMMUNOLOGY

Infectious Agents and Cancer Pub Date : 2025-05-23 DOI:10.1186/s13027-025-00658-y

Fahime Edalat, Arash Letafati, Tanin Kaghazchi, Mahdieh Sadeghi, Ali Taheri, Alireza Shikki, Samira Hossein Garkani, Mehdi Afrozi, Mehdi Norouzi, Sayed-Hamidreza Mozhgani

{"title":"HTLV-1 infection and microRNAs: unraveling the complex crosstalk.","authors":"Fahime Edalat, Arash Letafati, Tanin Kaghazchi, Mahdieh Sadeghi, Ali Taheri, Alireza Shikki, Samira Hossein Garkani, Mehdi Afrozi, Mehdi Norouzi, Sayed-Hamidreza Mozhgani","doi":"10.1186/s13027-025-00658-y","DOIUrl":null,"url":null,"abstract":"<p><p>Human T-cell leukemia virus type 1 (HTLV-1) retrovirus that infects millions of individuals worldwide, have caused severe diseases like adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Despite extensive research efforts, the underlying mechanisms leading to HTLV-1 pathogenesis remain incompletely understood. New research has revealed that microRNAs (miRNAs) play a crucial role in the complex interplay between HTLV-1 infection and host cellular responses. This review highlights the multifaceted interactions between HTLV-1 and miRNAs, encompassing both viral manipulation of cellular miRNA networks and host miRNA-mediated responses. Gaining a comprehensive understanding of the complex interconnection between HTLV-1 infection and miRNAs provides a significant opportunity for discovering innovative therapeutic approaches and creating advanced diagnostic tools aimed in HTLV-1 treatment.</p>","PeriodicalId":13568,"journal":{"name":"Infectious Agents and Cancer","volume":"20 1","pages":"33"},"PeriodicalIF":3.1000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100943/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Agents and Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13027-025-00658-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Human T-cell leukemia virus type 1 (HTLV-1) retrovirus that infects millions of individuals worldwide, have caused severe diseases like adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Despite extensive research efforts, the underlying mechanisms leading to HTLV-1 pathogenesis remain incompletely understood. New research has revealed that microRNAs (miRNAs) play a crucial role in the complex interplay between HTLV-1 infection and host cellular responses. This review highlights the multifaceted interactions between HTLV-1 and miRNAs, encompassing both viral manipulation of cellular miRNA networks and host miRNA-mediated responses. Gaining a comprehensive understanding of the complex interconnection between HTLV-1 infection and miRNAs provides a significant opportunity for discovering innovative therapeutic approaches and creating advanced diagnostic tools aimed in HTLV-1 treatment.

查看原文本刊更多论文

HTLV-1感染和microrna：解开复杂的串扰。

人类t细胞白血病病毒1型（HTLV-1）逆转录病毒感染了全世界数百万人，导致了严重的疾病，如成人t细胞白血病/淋巴瘤（ATLL）和HTLV-1相关的脊髓病/热带痉挛性截瘫（HAM/TSP）。尽管进行了广泛的研究，但导致HTLV-1发病机制的潜在机制仍然不完全清楚。新的研究表明，microRNAs （miRNAs）在HTLV-1感染与宿主细胞反应之间的复杂相互作用中起着至关重要的作用。这篇综述强调了HTLV-1和miRNA之间多方面的相互作用，包括病毒对细胞miRNA网络的操纵和宿主miRNA介导的反应。全面了解HTLV-1感染与mirna之间的复杂联系，为发现创新的治疗方法和创建针对HTLV-1治疗的先进诊断工具提供了重要机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infectious Agents and Cancer ONCOLOGY-IMMUNOLOGY

CiteScore

5.80

自引率

2.70%

发文量

期刊介绍： Infectious Agents and Cancer is an open access, peer-reviewed online journal that encompasses all aspects of basic, clinical, epidemiological and translational research providing an insight into the association between chronic infections and cancer. The journal welcomes submissions in the pathogen-related cancer areas and other related topics, in particular: • HPV and anogenital cancers, as well as head and neck cancers; • EBV and Burkitt lymphoma; • HCV/HBV and hepatocellular carcinoma as well as lymphoproliferative diseases; • HHV8 and Kaposi sarcoma; • HTLV and leukemia; • Cancers in Low- and Middle-income countries. The link between infection and cancer has become well established over the past 50 years, and infection-associated cancer contribute up to 16% of cancers in developed countries and 33% in less developed countries. Preventive vaccines have been developed for only two cancer-causing viruses, highlighting both the opportunity to prevent infection-associated cancers by vaccination and the gaps that remain before vaccines can be developed for other cancer-causing agents. These gaps are due to incomplete understanding of the basic biology, natural history, epidemiology of many of the pathogens that cause cancer, the mechanisms they exploit to cause cancer, and how to interrupt progression to cancer in human populations. Early diagnosis or identification of lesions at high risk of progression represent the current most critical research area of the field supported by recent advances in genomics and proteomics technologies.